Methods for Establishing and Evaluating Animal Models of Acute Liver Injury
Methods for Establishing and Evaluating Animal Models of Acute Liver Injury
Animal models of acute liver injury are used to simulate hepatocellular necrosis, inflammatory responses, oxidative stress, cholestasis, or metabolic disorders occurring within a short period of time. They are important experimental systems for studying mechanisms of liver injury, evaluating hepatoprotective agents, and screening intervention targets. Commonly used models include carbon tetrachloride-, acetaminophen-, concanavalin A-, D-galactosamine/lipopolysaccharide-, and ethanol-induced models. Different models differ in injury mechanism, modeling time, and evaluation indicators.
Keywords: acute liver injury; animal model; carbon tetrachloride; acetaminophen; concanavalin A; D-GalN/LPS; alcoholic liver injury; liver function indicators
1 Experimental Positioning of Animal Models of Acute Liver Injury
1.1 Objectives of Model Establishment
(1) Mechanistic studies
Acute liver injury models can be used to analyze hepatocellular necrosis, mitochondrial injury, oxidative stress, inflammatory factor release, immune cell activation, and abnormal bile excretion. Different inducers correspond to different pathological mechanisms. Therefore, the research focus should be clarified before selecting the modeling strategy.
(2) Pharmacodynamic evaluation
Screening of hepatoprotective drugs, antioxidants, anti-inflammatory agents, metabolic regulators, and natural products often requires stable acute liver injury models. If the injury is too mild, pharmacological effects may be difficult to distinguish; if the injury is too severe, animal mortality may increase or the therapeutic window may become too narrow. Therefore, preliminary experiments should be conducted before formal studies to determine the appropriate dose and sampling time.
(3) Indicator validation
Acute liver injury models can be used to validate detection systems for ALT, AST, LDH, total bilirubin, total bile acids, oxidative stress indicators, inflammatory factors, and pathological scoring. A single indicator usually cannot fully reflect the severity of liver injury; comprehensive evaluation should combine serum biochemistry, histopathology, and molecular mechanistic indicators.
1.2 Basis for Model Selection
(1) Matching injury mechanisms
Carbon tetrachloride is more suitable for studying free radical injury and lipid peroxidation. Acetaminophen is more suitable for simulating drug-induced liver injury. Concanavalin A is suitable for studies of T cell- and immune-mediated liver injury. D-GalN/LPS is suitable for studies of cytokine- and endotoxin-associated acute liver injury. Ethanol models are more suitable for research related to alcohol metabolism, lipid deposition, and oxidative stress.
(2) Observation time window
Acute liver injury is strongly time-dependent. In CCl4 and APAP models, marked serum transaminase elevation and pathological injury often appear within several hours to 24 h after administration. Inflammatory responses develop more rapidly in ConA and D-GalN/LPS models, whereas ethanol models are closely related to administration regimen, dose, and feeding status.
(3) Control of animal status
Animal strain, sex, age, body weight, fasting status, route of administration, and environmental stress can all affect model stability. APAP models are particularly affected by fasting and hepatic glutathione reserves, while immune-mediated models are more sensitive to animal immune status and the stability of tail vein injection.
Table 1 Key Points for Selecting Animal Models of Acute Liver Injury
Model Type | Representative Inducer | Main Mechanism | Modeling Characteristics | Suitable Research Directions |
Chemical liver injury | Free radical generation, lipid peroxidation, cell membrane injury | High modeling success rate and good reproducibility | Oxidative stress, hepatocellular necrosis, and liver repair | |
Drug-induced liver injury | NAPQI accumulation, GSH depletion, mitochondrial injury | Strong relevance to clinical drug-induced liver injury | Drug-induced liver injury, detoxification metabolism, and mitochondrial injury | |
T cell-mediated liver injury | T cell/NK cell activation and inflammatory factor release | Rapid inflammatory response with clear immune features | Immune hepatitis and T cell-mediated inflammation | |
Endotoxin-associated liver injury | Hepatocyte sensitization and TNF-α-mediated injury | Rapid modeling and marked inflammatory factor elevation | Endotoxemia, inflammatory factors, and mechanisms of liver failure | |
Alcoholic liver injury | Ethanol | Oxidative stress, lipid metabolism disorder, endotoxin translocation | Strongly dependent on administration regimen | Alcoholic liver injury, steatosis, and the gut-liver axis |
2 Chemical and Drug-Induced Acute Liver Injury Models
2.1 Carbon Tetrachloride-Induced Model
(1) Injury mechanism
Carbon tetrachloride (CCl4) is a classical inducer of chemical liver injury. After metabolism by hepatic CYP enzyme systems, CCl4 generates trichloromethyl radicals and trichloromethyl peroxy radicals. These free radicals attack polyunsaturated fatty acids in cell and mitochondrial membranes, leading to lipid peroxidation, increased membrane permeability, calcium homeostasis disruption, and hepatocellular necrosis.
(2) Modeling points
CCl4 is usually diluted in vegetable oil or mineral oil before administration. It can be administered by intraperitoneal injection, oral gavage, subcutaneous injection, or other routes. Different administration routes correspond to different absorption rates and injury intensities. Acute models commonly use a single administration followed by short-term sampling, and are often used to observe serum ALT and AST elevation, hepatic necrosis, increased MDA, decreased GSH, and altered SOD activity.
(3) Applications and limitations
The CCl4 model is relatively simple to establish, has a high success rate, and shows good reproducibility. It is suitable for studies of oxidative stress, lipid peroxidation, hepatocellular necrosis, and injury repair. However, excessive model intensity may cause animal death or narrow the pharmacological observation window. If sampling is performed after the optimal time point, hepatic self-repair may affect the interpretation of ALT, AST, and pathological results.
2.2 Acetaminophen-Induced Model
(1) Injury mechanism
After overdose, acetaminophen (APAP) is metabolized in the liver by enzymes such as CYP2E1 to generate the highly reactive intermediate NAPQI. Under normal conditions, small amounts of NAPQI are cleared by glutathione. When GSH is depleted, NAPQI binds to mitochondrial proteins, causing mitochondrial oxidative stress, ATP depletion, and hepatocellular necrosis.
(2) Modeling points
The APAP model is commonly used to simulate drug-induced acute liver injury. Animal fasting status before administration, APAP dissolution conditions, dosage, route of administration, and sampling time all significantly influence model intensity. APAP has poor water solubility; therefore, preparation conditions should be kept stable, and freshly prepared solutions should be used whenever possible to reduce precipitation and dosing deviation.
(3) Applications and limitations
The APAP model is closely related to clinical drug-induced liver injury and is suitable for studying drug metabolism, GSH depletion, mitochondrial injury, necroinflammation, and detoxification interventions. This model is sensitive to fasting, sex, strain, and metabolic status. If these conditions are not controlled consistently, large intra-group variation may occur.
Table 2 Comparison of Chemical and Drug-Induced Acute Liver Injury Models
Model | Main Mechanism | Common Evaluation Indicators | Main Advantages | Main Limitations |
CCl4 model | Free radical generation, lipid peroxidation, membrane injury | ALT, AST, MDA, SOD, GSH, hepatic necrosis | High modeling success rate; suitable for oxidative stress studies | Excessive dose may cause death; sampling time strongly affects results |
APAP model | NAPQI accumulation, GSH depletion, mitochondrial injury | ALT, AST, GSH, MDA, mitochondrial injury, necrotic area | Strong relevance to drug-induced liver injury | Strongly affected by fasting, dissolution conditions, and metabolic status |
3 Immune-Mediated Acute Liver Injury Models
3.1 Concanavalin A-Induced Model
(1) Injury mechanism
Concanavalin A (ConA) is a plant lectin that can activate T cells, NK cells, Kupffer cells, and multiple inflammatory pathways. It induces the release of inflammatory factors such as IFN-γ, TNF-α, and IL-6, and causes hepatocyte apoptosis or necrosis through immune cell-mediated inflammatory responses. This model is commonly used to study T cell-mediated hepatitis and mechanisms of immune liver injury.
(2) Modeling points
The ConA model is usually established by intravenous administration. Marked inflammatory responses and elevated transaminases can appear within a short time after administration. Model stability is influenced by animal strain, immune status, injection speed, solution condition, and tail vein injection technique. During experiments, operators and dosing conditions should be standardized as much as possible.
(3) Applications and limitations
The ConA model is suitable for studying immune cell activation, cytokine storm, T cell-mediated hepatitis, and evaluation of immunomodulatory drugs. This model requires relatively high technical proficiency in administration, and the inflammatory response progresses rapidly. Therefore, sampling time directly affects inflammatory factor levels, serum enzymology, and pathological findings.
3.2 D-GalN/LPS-Induced Model
(1) Injury mechanism
D-galactosamine (D-GalN) sensitizes hepatocytes to endotoxin, while lipopolysaccharide (LPS) activates TLR4-related inflammatory pathways and induces the release of cytokines such as TNF-α, IL-1β, and IL-6. Combined administration causes cytokine-mediated acute liver injury and is commonly used to simulate endotoxin-associated hepatitis and early processes of acute liver failure.
(2) Modeling points
The D-GalN/LPS model is usually established by combined administration, with rapid modeling and marked elevation of inflammatory factors. The ratio of D-GalN to LPS, administration timing, animal status, and sampling time should be carefully controlled. Preliminary experiments should be used to determine conditions that both produce stable injury and preserve a pharmacological evaluation window.
(3) Applications and limitations
This model is suitable for studying macrophage/Kupffer cell activation, TNF-α-mediated injury, inflammatory factor networks, and anti-inflammatory hepatoprotective drugs. If the model is too severe, mortality may increase, and excessive inflammatory responses may mask the protective effects of some interventions.
Table 3 Comparison of Immune-Mediated Acute Liver Injury Models
Model | Key Induction Process | Main Inflammatory Features | Common Indicators | Suitable Directions |
ConA model | T cell/NK cell activation | Increased IFN-γ, TNF-α, and IL-6 | ALT, AST, inflammatory factors, hepatic inflammatory infiltration | T cell-mediated hepatitis and immunomodulation studies |
Hepatocyte sensitization + endotoxin-induced inflammatory activation | Increased TNF-α, IL-1β, and IL-6 | ALT, AST, TNF-α, IL-6, apoptosis/necrosis indicators | Endotoxin-associated liver injury, inflammatory factors, and acute liver failure studies |
4 Alcoholic Acute Liver Injury Model
4.1 Ethanol-Induced Model
(1) Injury mechanism
Ethanol is mainly metabolized in the liver. Through pathways involving alcohol dehydrogenase, aldehyde dehydrogenase, and the microsomal ethanol-oxidizing system, ethanol generates acetaldehyde and reactive oxygen species, leading to oxidative stress, lipid metabolism disorder, triglyceride accumulation, and inflammatory responses. Ethanol can also increase intestinal permeability, allowing endotoxin to enter the portal venous system and activate Kupffer cells, thereby aggravating inflammatory liver injury.
(2) Modeling points
Acute ethanol-induced liver injury can be established by gavage, dietary intervention, injection, or other approaches. The specific regimen should be selected according to whether the study focuses on acute intoxication, steatosis, inflammatory response, or gut-liver axis alterations. Detection indicators may include ALT, AST, hepatic TG, MDA, GSH, inflammatory factors, and hepatic steatosis score.
(3) Applications and limitations
The ethanol model is suitable for studying alcohol metabolism, oxidative stress, steatosis, inflammatory injury, and gut-liver axis regulation. Results are strongly affected by diet, fasting, ethanol tolerance, administration route, and sampling time. If the research target is chronic alcoholic liver disease, longer-term dietary or chronic administration models should be used.
4.2 Differences Between Alcoholic Models and Other Models
(1) Injury characteristics
CCl4 and APAP models mainly involve toxic metabolites, free radicals, or mitochondrial injury. ConA and D-GalN/LPS models are dominated by immune-inflammatory responses. In contrast, ethanol models involve alcohol metabolism, oxidative stress, lipid deposition, and gut-derived endotoxin stimulation simultaneously. Model selection should therefore match the research question rather than be based only on modeling speed.
(2) Evaluation focus
In addition to ALT, AST, and pathological injury, ethanol models should place greater emphasis on hepatic lipid deposition, TG content, oxidative stress, inflammatory factors, and intestinal barrier-related indicators. If only transaminases are detected, the research value of steatosis and metabolic disorder in ethanol models may be underestimated.
Table 4 Application Comparison of Common Acute Liver Injury Models
Model Type | Representative Inducer | Main Pathological Features | Recommended Sampling Focus | More Suitable Research Question |
Chemical liver injury | Pericentral necrosis and lipid peroxidation | ALT, AST, MDA, SOD, GSH, pathological necrosis | Whether antioxidant and membrane-protective interventions are effective | |
Drug-induced liver injury | Mitochondrial injury, GSH depletion, hepatocellular necrosis | ALT, AST, GSH, mitochondrial injury, necrotic area | Whether drug toxicity and detoxification metabolism are regulated | |
T cell-mediated liver injury | Inflammatory infiltration and T cell-mediated necrosis | IFN-γ, TNF-α, IL-6, immune cell infiltration | Whether immune-inflammatory responses are suppressed | |
Endotoxin-associated liver injury | Elevated inflammatory factors and apoptosis/necrosis | TNF-α, IL-1β, IL-6, apoptosis indicators | Whether endotoxin inflammation and cytokine pathways are modulated | |
Alcoholic liver injury | Ethanol | Steatosis, oxidative stress, inflammatory response | TG, MDA, GSH, ALT, AST, steatosis score | Whether alcohol metabolism, lipid deposition, and the gut-liver axis are regulated |
5 Evaluation Indicators and Quality Control
5.1 Serum Biochemical Indicators
(1) Transaminase indicators
ALT and AST are the most commonly used serum indicators for evaluating acute hepatocellular injury. ALT is more specific to hepatocellular injury, whereas AST can also be affected by mitochondrial injury, muscle sources, and systemic status. In acute injury models, elevated ALT and AST generally indicate impaired hepatocyte membrane integrity, but interpretation should be combined with pathology and the time window.
(2) Bilirubin and bile acid indicators
Total bilirubin, direct bilirubin, and total bile acids can be used to evaluate changes related to hepatobiliary excretion and cholestasis. Not all acute liver injury models produce obvious changes in bilirubin or bile acids. Whether these indicators should be included depends on the model mechanism and research objective.
5.2 Histopathology and Cell Death Indicators
(1) Pathological evaluation
HE staining can reveal hepatocyte swelling, necrosis, inflammatory infiltration, steatosis, and tissue architecture disruption, and is an important basis for evaluating acute liver injury models. In CCl4 and APAP models, necrotic areas and disruption of hepatic lobular architecture are commonly emphasized, whereas in ethanol models, steatosis and inflammatory changes should receive greater attention.
(2) Cell death
TUNEL, cleaved caspase-3, Bax/Bcl-2, HMGB1, and related indicators can be used to distinguish apoptosis, necrosis, or inflammatory cell death-related processes. D-GalN/LPS and ConA models are more suitable for combined evaluation of inflammatory factors and apoptosis indicators, whereas APAP models should focus more on necrosis and mitochondrial injury-related indicators.
5.3 Oxidative Stress and Inflammatory Indicators
(1) Oxidative stress
MDA, GSH, T-GSH, GSH-Px, SOD, and ROS levels can be used to evaluate oxidative injury and antioxidant defense capacity. CCl4, APAP, and ethanol models can all include oxidative stress indicators, but the timing and degree of oxidative stress differ among models and should be matched with the sampling time.
(2) Inflammatory factors
TNF-α, IL-1β, IL-6, IFN-γ, MCP-1, and related factors can be used to evaluate inflammatory responses. The ConA model places greater emphasis on T cell/NK cell-related inflammation, the D-GalN/LPS model focuses more on the endotoxin-induced TNF-α pathway, and the ethanol model can be analyzed together with gut-derived endotoxin and Kupffer cell activation.
Table 5 Common Evaluation Indicators for Acute Liver Injury Models
Indicator Category | Representative Indicators | Main Significance | Applicable Models |
Liver function injury | ALT, AST, LDH | Hepatocyte membrane injury and enzyme release | All acute liver injury models |
Bile excretion | TBIL, DBIL, TBA | Cholestasis and biliary excretory status | Cholestasis-related models and severe liver injury models |
Oxidative stress | MDA, GSH, T-GSH, GSH-Px, SOD | Lipid peroxidation and antioxidant capacity | CCl4, APAP, and ethanol models |
Inflammatory factors | TNF-α, IL-1β, IL-6, IFN-γ | Inflammatory response and immune activation | ConA, D-GalN/LPS, and ethanol models |
Endotoxin response | LPS, LBP | Endotoxin exposure and gut-derived inflammatory response | D-GalN/LPS and ethanol models |
Histopathology | HE staining, necrotic area, inflammation score, steatosis score | Tissue architecture and degree of pathological injury | All acute liver injury models |
Cell death | TUNEL, cleaved caspase-3, Bax/Bcl-2, HMGB1 | Apoptosis, necrosis, or inflammatory injury | APAP, ConA, and D-GalN/LPS models |
6 Selection of Related Reagents and Materials
Table 6 Reagents Related to Establishing Animal Models of Acute Liver Injury
Cat. No. | Product Name | Grade & Purity | Model Type | Application Positioning |
Carbon tetrachloride standard solution | analytical standard, ≥99.9% | CCl4 chemical liver injury model | Used to establish carbon tetrachloride-induced acute liver injury models; suitable for studies of oxidative stress, lipid peroxidation, and hepatocellular necrosis | |
4-Acetamidophenol | AR, ≥99% | APAP drug-induced liver injury model | Used to establish acetaminophen-induced drug-induced acute liver injury models | |
4-Acetamidophenol | analytical standard, ≥99.5% | APAP drug-induced liver injury model/standard | Suitable for APAP model-related method validation, dose control, and analytical standard use | |
4-Acetamidophenol | ≥98% | APAP drug-induced liver injury model | Used for establishment of drug-induced liver injury models and APAP-related experimental systems | |
Concanavalin A lectin (Con A) | ≥90% | ConA immune-mediated liver injury model | Used in ConA-induced acute immune liver injury experiments | |
D-(+)-Galactosamine hydrochloride | ≥99% | D-GalN/LPS immune-inflammatory liver injury model | Used together with LPS to establish D-GalN/LPS-induced acute liver injury models | |
D-(+)-Galactosamine hydrochloride | for cell culture, ≥99% | D-GalN/LPS immune-inflammatory liver injury model | Used in D-GalN-related cellular or animal experimental systems | |
Lipopolysaccharide (LPS) Solution (500X) | sterile-filtered,BioReagent,500X (1mg/mL) | D-GalN/LPS model/endotoxin stimulation | Used for LPS-related inflammatory stimulation, D-GalN/LPS models, or in vitro inflammatory validation | |
Lipopolysaccharides from Escherichia coli O111:B4 | purified by phenol extraction | D-GalN/LPS model/endotoxin stimulation | Used for endotoxin-associated acute liver injury and inflammatory factor release studies | |
Lipopolysaccharide(LPS) | Derived from Escherichia coli 055:B5, purified by trichloroacetic acid extraction | D-GalN/LPS model/endotoxin stimulation | Suitable for LPS-induced inflammatory responses and D-GalN combined modeling | |
Lipopolysaccharides from Escherichia coli O127:B8 | γ-irradiated, BioReagent, for cell culture | LPS inflammatory stimulation | Used for endotoxin inflammatory stimulation in cell culture systems | |
Lipopolysaccharides from Escherichia coli O26:B6 | γ-irradiated, BioReagent, for cell culture | LPS inflammatory stimulation | Used for in vitro studies of Kupffer cells, macrophages, or inflammatory pathways |
Table 7 Products for Evaluating Liver Function and Cholestasis in Acute Liver Injury
Cat. No. | Product Name | Grade & Purity | Indicator Category | Application Positioning |
Alanine Aminotransferase (ALT/GPT) Activity Assay Kit (DNPH, Micro Method) | BioReagent | Liver function injury | Used for ALT activity detection in serum, plasma, or tissue samples; a core indicator for evaluating acute hepatocellular injury | |
Mouse Aspartate Aminotransferase (AST) ELISA Kit | BioReagent | Mouse AST detection | Used for AST-related detection in mouse acute liver injury models | |
Human Aspartate Aminotransferase 2/Glutamic-oxaloacetic Transaminase 2 (AST2/GOT2) ELISA Kit | BioReagent | AST2/GOT2 detection | More suitable for human samples or mechanistic studies; not the preferred liver function indicator for mouse acute liver injury models | |
Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (DNPH, Micro Method) | BioReagent | Cell injury/cytotoxicity | Used for evaluating LDH release and cell membrane integrity damage | |
Lactate Dehydrogenase (LDH) Activity Assay Kit (LD-L, Colorimetric Method) | BioReagent | LDH activity | Used for detecting LDH activity in serum, tissue, or cell samples | |
Lactate Dehydrogenase (LDH) Activity Assay Kit (LD-P, UV Colorimetric Method) | BioReagent | LDH activity | Used for LDH activity detection in UV colorimetric systems | |
Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (DNPH, Colorimetric Method) | BioReagent | Cytotoxicity | Used for evaluating hepatocyte cytotoxicity, drug intervention, and cell injury | |
Total Bilirubin (TBIL) Content Assay Kit (Micro Method) | BioReagent | Bilirubin metabolism/cholestasis | Used for total bilirubin detection; suitable for evaluation of severe acute liver injury and abnormal bile excretion | |
Direct Bilirubin (DBIL) Content Assay Kit (Micro Method) | BioReagent | Direct bilirubin/bile excretion | Used for direct bilirubin detection; suitable for evaluating cholestasis, biliary excretory abnormalities, and severe liver injury | |
Total Bile Acids (TBA) Content Assay Kit (Micro Method) | BioReagent | Bile acid metabolism/cholestasis | Used for total bile acid detection; suitable for evaluating hepatobiliary excretory abnormalities, cholestasis, and liver injury-related bile acid metabolism | |
Urine Bilirubin Qualitative Detection Kit (Harrison's Method) | BioReagent | Urinary bilirubin | Used for auxiliary urine-based detection related to bile pigment metabolism; suitable for expanded evaluation of hepatobiliary excretory abnormalities |
Table 8 Products for Evaluating Oxidative Stress, Inflammation, and Pathology in Acute Liver Injury
Cat. No. | Product Name | Grade & Purity | Indicator Category | Application Positioning |
Malondialdehyde (MDA) Content Assay Kit (TBA, Colorimetric Method) | BioReagent | Lipid peroxidation | Used for detecting hepatic MDA content in CCl4, APAP, ethanol, and other models | |
Malondialdehyde (MDA) Content Assay Kit (TBA, Fluorometric Method) | BioReagent | Lipid peroxidation | Used for low-content samples or high-sensitivity MDA detection | |
Lipid Peroxidation (MDA) Assay Kit | sufficient for 100colorimetricorfluorometrictests | Lipid peroxidation | Used for detecting lipid oxidation levels; suitable for oxidative stress injury evaluation | |
Rat Malondialdehyde(MDA) ELISA Kit | BioReagent | Rat MDA detection | Used for MDA-related detection in rat acute liver injury models | |
Total Glutathione (T-GSH) Content Assay Kit (DTNB, Micro Method) | BioReagent | Glutathione system | Used for total glutathione detection; suitable for evaluating antioxidant capacity in APAP, CCl4, and ethanol models | |
Total Glutathione (T-GSH) Content Assay Kit (DTNB, Colorimetric Method) | BioReagent | Glutathione system | Used for colorimetric detection of total glutathione content | |
Reduced Glutathione (GSH) Content Assay Kit (DTNB, Micro Method) | BioReagent | GSH content | Used for evaluating GSH depletion and antioxidant capacity, especially in APAP models | |
Reduced Glutathione (GSH) Content Assay Kit (DTNB, Colorimetric Method) | BioReagent | GSH content | Used for colorimetric detection of GSH content | |
Glutathione Peroxidase (GSH-Px) Activity Assay Kit (DTNB, Micro Method) | BioReagent | Antioxidant enzyme activity | Used for detecting GSH-Px activity; suitable for oxidative stress and antioxidant defense evaluation | |
Glutathione Peroxidase (GSH-Px) Activity Assay Kit (DTNB, Colorimetric Method) | BioReagent | Antioxidant enzyme activity | Used for colorimetric detection of GSH-Px activity | |
Total Superoxide Dismutase (SOD) Assay Kit (NBT Riboflavin Microplate Method) | BioReagent | SOD activity | Used for microplate-based total SOD detection; suitable for evaluating hepatic antioxidant capacity | |
Total Superoxide Dismutase (SOD) Assay Kit (NBT Riboflavin Colorimetric Method) | BioReagent | SOD activity | Used for colorimetric total SOD detection | |
Total Superoxide Dismutase (T-SOD) Activity Assay Kit (WST-8, Micro Method) | BioReagent | SOD activity | Used for total SOD activity detection in the WST-8 system | |
Total Superoxide Dismutase (SOD) Activity Assay Kit (Pyrogallol, UV Colorimetric Method) | BioReagent | SOD activity | Used for SOD activity detection in UV colorimetric systems | |
Rat Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit | BioReagent | Inflammatory factor | Used for TNF-α detection in rat acute liver injury models | |
Mouse Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit | BioReagent | Inflammatory factor | Used for TNF-α detection in mouse acute liver injury models | |
Mouse Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit | BioReagent | Inflammatory factor | Used for TNF-α detection in mouse inflammatory liver injury | |
Rat Interleukin 6 (IL-6) ELISA Kit | BioReagent | Inflammatory factor | Used for IL-6 detection in rat acute liver injury models | |
Mouse Interleukin 6 (IL-6) ELISA Kit | BioReagent | Inflammatory factor | Used for IL-6 detection in mouse acute liver injury models | |
Mouse Interleukin 6 (IL-6) ELISA Kit | BioReagent | Inflammatory factor | Used for IL-6 detection in mouse inflammatory liver injury | |
Rat Lipopolysaccharide (LPS) ELISA Kit | BioReagent | Endotoxin-related indicator | Used for evaluating endotoxin responses in rat D-GalN/LPS or ethanol-related models | |
Mouse Lipopolysaccharides(LPS) ELISA Kit | BioReagent | Endotoxin-related indicator | Used for detecting LPS-related inflammatory responses and endotoxin levels in mice | |
Rat Lipopolysaccharide Binding Protein (LBP) ELISA Kit | BioReagent | Endotoxin-binding protein | Used for studies of endotoxin responses, gut-derived LPS translocation, and inflammatory mechanisms in rats | |
Mouse Lipopolysaccharide Binding Protein (LBP) ELISA Kit | BioReagent | Endotoxin-binding protein | Used for studies of endotoxin responses and D-GalN/LPS model mechanisms in mice | |
Modified Hematoxylin-Eosin (HE) Staining Kit | BioReagent,for cell culture,for microscopy | Histopathology | Used for observing hepatic necrosis, inflammatory infiltration, and tissue architecture | |
Hematoxylin-Eosin (HE) High-Definition Consistent Staining Kit (High-Definition Stable Staining) | BioReagent,for microscopy,Biological Stain | Histopathology | Used for HE staining and pathological evaluation of liver tissue | |
Hematoxylin-Eosin (HE) Staining Kit (with Differentiating Solution) | BioReagent,for microscopy,Biological Stain | Histopathology | Used for routine HE staining; suitable for pathological analysis of acute liver injury | |
Hematoxylin-Eosin (HE) Staining Kit (with Differentiating Solution and Bluing Solution) | BioReagent,for microscopy,Biological Stain | Histopathology | Used for HE staining and pathological morphology observation of liver tissue | |
Bile Pigment Staining Solution (Modified Fouchet Method) | BioReagent, Biological Stain, for microscopy | Bile pigment staining | Used for histological observation of bile pigment deposition, cholestasis, or bilirubin-related changes | |
Biotin TUNEL apoptosis Kit |
| Cell death | Used for detecting apoptosis in liver tissue or cells | |
Colorimetric TUNEL Apoptosis Assay Kit | BioReagent,比色法,for microscopy | Cell death | Used for chromogenic TUNEL detection; suitable for microscopic observation of tissue sections | |
Aladdin ® 488 TUNEL apoptosis Kit (green fluorescence) |
| Cell death | Used for fluorescent TUNEL detection; suitable for localization analysis of apoptotic cells | |
Aladdin ® 555 TUNEL apoptosis Kit (orange red fluorescence) |
| Cell death | Used for fluorescent TUNEL detection and combination with multiplex staining | |
Aladdin ® 594 TUNEL apoptosis Kit (red fluorescence) |
| Cell death | Used for red fluorescent TUNEL detection | |
Aladdin ® 640 TUNEL apoptosis Kit (far red fluorescence) |
| Cell death | Used for far-red fluorescent TUNEL detection; suitable for multicolor immunofluorescence experiments |
7 Frequently Asked Questions
7.1 Should CCl4 or APAP be selected for acute liver injury modeling?
CCl4 is more suitable for studying free radical injury, lipid peroxidation, and membrane structure disruption, whereas APAP is more suitable for studying drug-induced liver injury, GSH depletion, and mitochondrial injury. If the experimental objective is to screen antioxidant hepatoprotective agents, the CCl4 model can be prioritized. If the focus is drug metabolic toxicity or detoxification mechanisms, the APAP model is more appropriate.
7.2 What is the difference between the ConA model and the D-GalN/LPS model?
The ConA model is more oriented toward T cell- and NK cell-mediated immune liver injury and is suitable for studying immune hepatitis and T cell-related inflammation. The D-GalN/LPS model is more oriented toward endotoxin-, macrophage-, and TNF-α-mediated injury and is suitable for studying inflammatory factor networks and early mechanisms of acute liver failure.
7.3 Why do results decline after a certain time point in the CCl4 model?
After acute CCl4 injury, the liver has strong self-repair capacity. If sampling is too late, ALT and AST may begin to decrease, and the necrotic area may enter the repair phase, affecting the interpretation of injury severity and pharmacological efficacy.
CCl4 is suitable for oxidative stress and membrane injury studies, APAP is suitable for drug-induced hepatotoxicity studies, ConA and D-GalN/LPS are suitable for immune inflammation-related studies, and ethanol models are suitable for studies of alcohol metabolism, lipid deposition, and the gut-liver axis.
For more related articles, please see below:
[1] The Technology Driving Biomedical Revolution — Animal Modeling
[2] Animal Modeling—Tumor Disease Models
[3] A Detailed Guide to the Construction of Animal Models for Metabolic Diseases
[4] Methods for Establishing Animal Models of Cardiovascular Diseases
[5] Methods for Establishing Models of Nervous System Diseases
[6] Construction of a subcutaneous hormonal tumor model of melanoma
